InsidersTradesSigma
Follow the Metagenomi Therapeutics, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Market capitalisation: €45.6m. The latest transaction was reported on 3 April 2026 (Attribution). Among the most active insiders: Wapnick Pamela. The full history is free.
Analysts rate Metagenomi Therapeutics, Inc. Strong Buy (bullish), based on 3 analysts. Average price target: US$7.67.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
6 of 6 declarations
Metagenomi Therapeutics, Inc. is a biotechnology company focused on developing innovative gene therapies. It leverages advanced technologies to address genetic diseases and other medical conditions.